Puteaux, France -- ELITechGroup today announced a distribution agreement with Abbott Molecular, Inc. for U.S. distribution of molecular diagnostic reagents. The reagents included in the agreement are focused on monitoring virus activity in patients that have undergone organ or hematopoietic stem cell transplantation. Other products included in the agreement will focus on the expanding need to test for additional sexually transmitted infections beyond Chlamydia and Gonorrhea. The agreement will provide a broader based distribution of ELITechGroup MGB Alert Analyte Specific Reagents. It is anticipated that the ELITechGroup products will be available from Abbott Molecular in early 2017.
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced positive initial safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY trial and from the first transfusion-dependent beta thalassemia patient treated in the EdiTHAL trial.
The RUBY trial data will be presented in an oral presentation at European Hematology Association (EHA) Hybrid Congress in Frankfurt, Germany, and via live stream on Saturday, June 10,...
CD Genomics is a leading global life sciences company committed to providing the research community with high-quality long-read sequencing services, from Oxford Nanopore to PacBio SMRT sequencing. The Product Manager of the Long-Read Sequencing Division announced the launch of the Human Leukocyte Antigen (HLA) Typing service to support high-resolution HLA typing in a rapid and cost-efficient manner.
HLA is a group of glycoproteins that play an important role in the body’s immune system, encoded by the...
BIOtechNOW featured IVS’s participating BIO Innovation Zone
Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies.
The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the...
BIO Investor Forum Company Snapshot: InvivoSciences
What is your company’s lead product or technology?
InvivoSciences, Inc. (IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. IVS’s Functional 3D tissue models recapitulate the physiological properties of human cardiac, smooth and skeletal muscle and connective...
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart tissues are fabricated with cardiomyocytes derived from human induced pluripotent stem cells. The ultra- sensitive plate...
Customer comments
No comments were found for Abbott Molecular distribution of ELITechGroup products will expand distribution channels. Be the first to comment!
